Gland Pharma Hits INR 1,800 Cr Revenue as Q1 Profit Surges 47%

Gland Pharma reported a strong Q1 profit. The company posted revenue of INR 1,800.27 crore in Q1 FY27. Its net profit rose 47.1% year over year to INR 316.95 crore.

The company’s Q1 revenue grew 19.6% from INR 1,505.17 crore in the same quarter last year. Gland Pharma also reported EBITDA of INR 489.36 crore during the quarter. EBITDA increased 29.8% year over year from INR 377.03 crore.

The company’s US business remained a major growth driver during the quarter. Gland Pharma continued to focus on complex injectables and specialty pharmaceutical products.

The company also saw growth across its key markets. Its portfolio includes sterile injectables, oncology products, ophthalmic products, and other specialty medicines.

Key Q1 FY27 financial highlights include:

• Revenue from operations stood at INR 1,800.27 crore.
• Net profit increased 47.1% year over year.
• EBITDA reached INR 489.36 crore.
• EBITDA margin improved to around 27.2%.
• Revenue increased 19.6% year over year.
• The company continued to expand its presence in global pharmaceutical markets.

Also Read: AI in Drug Discovery and Development: From Lab to Commercial Market

Strong Profit Growth Supports FY27 Outlook

The rise in profit was stronger than the growth in revenue. This points to better operating performance during the quarter. Gland Pharma has been strengthening its focus on complex products. The company is also expanding its manufacturing and product capabilities.

Its global operations remain important to the business. The US market continues to offer opportunities for higher-value pharmaceutical products. The company’s injectable portfolio remains a key part of its business strategy. It also continues to work on new product launches and regulatory approvals.

"Growth was driven by recent product launches from the CDMO portfolio and strong customer demand for our diversified product mix. We continue to strengthen our platform through investments in differentiated technologies and capacity expansions, which position us well for sustainable long-term growth." said Srinivas Sadu, Executive Chairman, Gland Pharma.

What the Q1 Results Mean

• Revenue growth: 19.6% year over year
• Net profit growth: 47.1% year over year
• Q1 revenue: INR 1,800.27 crore
• Q1 net profit: INR 316.95 crore
• EBITDA: INR 489.36 crore
• EBITDA growth: 29.8% year over year

The Q1 profit give Gland Pharma a strong start to the new financial year. The company’s profit growth also outpaced revenue growth during the quarter. With continued demand for complex injectables, global expansion could remain important. The company’s performance will be closely watched through the rest of FY27.